CA14 Antibody

What is the molecular weight of CA14 protein and how does this compare to observed weights in Western blot applications?

The calculated molecular weight of human CA14 is approximately 38 kDa (337 amino acids), but observed molecular weights in Western blot experiments typically range from 42-54 kDa . This discrepancy is likely due to post-translational modifications, particularly glycosylation. When performing Western blots, researchers should expect bands at:

• 42 kDa in human, mouse, and rat brain (cerebellum) tissue and Hepa 1-6 mouse hepatoma cell line under reducing conditions

• 54 kDa in mouse and rat brain (cerebellum) tissue using Simple Western methodology

• 45-50 kDa as commonly observed with antibody 13736-1-AP

Which tissues show highest expression of CA14 and are therefore optimal for positive controls?

CA14 is highly expressed in all parts of the central nervous system, with brain tissue (particularly cerebellum) serving as excellent positive controls for antibody validation . Other tissues with lower but detectable expression include:

• Adult liver (especially hepatocytes with predominance in the canalicular membrane)

• Heart

• Small intestine

• Colon

• Kidney

• Urinary bladder

• Skeletal muscle

• Retina and eye tissue

For Western blot positive controls, mouse eye tissue, mouse retina tissue, and cerebellum samples have been successfully used and validated .

What are the primary applications for CA14 antibodies in research?

Based on available validation data, CA14 antibodies are predominantly used in:

The experimental approach should be guided by the specific research question, with Western blot being the most thoroughly validated application across multiple antibodies .

How should researchers select the optimal CA14 antibody based on epitope targeting?

Different CA14 antibodies target distinct regions of the protein, which impacts their performance in specific applications:

When designing experiments, consider:

• The accessibility of the epitope in your experimental conditions

• Whether post-translational modifications might affect antibody binding

• The need to detect specific isoforms or truncated versions

• The requirement for cross-species reactivity

What are the optimal storage and handling conditions for CA14 antibodies to maintain reactivity?

To preserve antibody functionality and prevent degradation:

• Store concentrated antibody stocks at -20°C to -70°C for long-term storage (12 months from date of receipt)

• For frequent use and short-term storage (up to 1 month), keep at 4°C under sterile conditions after reconstitution

• Avoid repeated freeze-thaw cycles, which can damage antibody structure and reduce activity

• For extended storage (6 months), maintain at -20°C to -70°C under sterile conditions after reconstitution

• Some antibodies are supplied in stabilizing buffers containing:

  • PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide

  • PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

These storage recommendations ensure maximum antibody performance and extended shelf-life .

What controls should be included when validating a new CA14 antibody?

A comprehensive validation strategy should include:

• Positive tissue controls:

  • Cerebellum tissue from relevant species (human, mouse, rat)

  • Mouse eye tissue and retina tissue

  • Hepa 1-6 mouse hepatoma cell line

• Negative controls:

  • Tissues known to lack CA14 expression

  • Secondary antibody-only controls

  • Isotype controls (rabbit IgG for most CA14 antibodies)

• Specificity controls:

  • Blocking peptide competition assays using synthetic peptides derived from the immunogen sequence

  • Comparison with multiple antibodies targeting different epitopes

  • siRNA knockdown or knockout validation where possible

• Loading and transfer controls:

  • Housekeeping protein detection (β-actin, GAPDH)

  • Total protein staining (Ponceau S, SYPRO Ruby)

How do CA14 antibodies perform across species and what are the considerations for cross-reactivity studies?

Cross-reactivity profiles vary significantly between antibodies:

When planning cross-species studies:

• Compare sequence homology in the epitope region across species

• Validate antibody in each species separately before comparative studies

• Consider species-specific differences in protein size and post-translational modifications

• Test for non-specific binding in each species using appropriate controls

What methodological approaches can improve detection sensitivity in low CA14 expression contexts?

For tissues or cells with low CA14 expression:

• Optimize protein extraction:

  • Use membrane protein enrichment protocols (CA14 is a type I membrane protein)

  • Include protease inhibitors to prevent degradation

  • Consider detergent selection carefully (RIPA vs. NP-40 vs. Triton X-100)

• Western blot optimization:

  • Increase antibody concentration (1:500 rather than 1:2000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use high-sensitivity ECL substrates

  • Load more total protein (50-100 μg instead of standard 20-30 μg)

• Signal amplification methods:

  • Implement tyramide signal amplification for IHC/IF

  • Use biotin-streptavidin amplification systems

  • Consider more sensitive detection systems like Simple Western™ methodology, which detected CA14 in samples where traditional Western blot showed weaker signals

• Reducing background:

  • Optimize blocking conditions (5% milk vs. 5% BSA)

  • Include additional washing steps

  • Use highly purified antibodies (>95% purity)

How can researchers distinguish between different carbonic anhydrase isoforms when studying CA14?

The carbonic anhydrase family contains multiple isoforms with similar structure and function. To specifically detect CA14:

• Antibody selection strategies:

  • Choose antibodies that target unique regions of CA14 not conserved in other CA isoforms

  • Verify specificity against recombinant CA14 versus other CA family members

  • Use epitope mapping to confirm target specificity

• Experimental validation approaches:

  • Perform parallel detection with multiple CA14 antibodies targeting different epitopes

  • Include known positive controls for other CA isoforms to confirm absence of cross-reactivity

  • Consider molecular weight differences (CA14 appears at 42-54 kDa while other CAs may appear at different sizes)

• Molecular techniques for discrimination:

  • Use RT-PCR with isoform-specific primers before protein studies

  • Consider immunoprecipitation followed by mass spectrometry for definitive identification

  • Employ knockout/knockdown models when available to confirm specificity

What explains the discrepancies in observed molecular weights between different detection methods?

Several factors contribute to the observed molecular weight variations:

• Post-translational modifications:

  • Glycosylation adds substantial mass to the core protein

  • Phosphorylation and other modifications can alter mobility

• Methodological differences:

  • Simple Western™ detection showed CA14 at approximately 54 kDa

  • Traditional Western blot typically shows 42 kDa bands

  • Proteintech antibody 13736-1-AP shows 45-50 kDa bands

• Sample preparation effects:

  • Different lysis buffers can affect protein conformation and SDS binding

  • Heat denaturation temperature and duration influence mobility

  • Reducing vs. non-reducing conditions impact observed size

• Technical considerations:

  • Gel percentage affects relative migration

  • Running buffer composition influences mobility

  • Molecular weight marker calibration variations

When reporting CA14 detection, researchers should always specify the experimental conditions and expected size range based on their specific antibody and methodology .

How should researchers address inconsistent or unexpected CA14 antibody performance?

When faced with antibody performance issues:

• Systematic troubleshooting protocol:

  • Verify antibody storage conditions and expiration

  • Test fresh aliquots to rule out degradation

  • Titrate antibody concentration across a wider range (1:500-1:6000 for WB)

  • Modify blocking agents (switch between milk and BSA)

• Sample-specific considerations:

  • Ensure proper tissue preparation and protein extraction

  • Include protease and phosphatase inhibitors

  • Consider the impact of sample processing on epitope accessibility

  • Test multiple positive control tissues (cerebellum, eye tissue, retina)

• Technical optimization:

  • Adjust exposure times for Western blot

  • Modify antigen retrieval methods for IHC/IF

  • Test alternative secondary antibodies

  • Consider using signal enhancement systems

• Antibody validation strategies:

  • Compare performance across multiple antibodies

  • Use blocking peptides to confirm specificity

  • Consider collaborative validation with other laboratories

What are the key considerations when designing multiplex experiments that include CA14 detection?

For successful multiplex experiments:

• Antibody compatibility planning:

  • Select CA14 antibodies from different host species than other target antibodies

  • Verify that secondary antibodies do not cross-react

  • Consider directly conjugated primary antibodies to avoid secondary antibody issues

• Signal separation strategies:

  • Plan fluorophore selection to minimize spectral overlap

  • Account for expression level differences between targets

  • Establish single-stain controls for each antibody

• Optimization requirements:

  • Test each antibody individually before multiplexing

  • Determine optimal concentration for each antibody separately

  • Verify that antibody performance isn't compromised in multiplex buffers

• Technical considerations:

  • Implement appropriate blocking to prevent non-specific binding

  • Include controls for autofluorescence and background

  • Consider sequential rather than simultaneous staining for challenging combinations

How can CA14 antibodies be utilized in neuroscience research given the enzyme's expression pattern?

CA14's high expression in the central nervous system makes these antibodies valuable for neuroscience research:

• Neuroanatomical mapping applications:

  • CA14 can serve as a marker for specific neuronal populations

  • IHC and IF applications can map regional distribution patterns

  • Co-localization studies with neuronal or glial markers provide insights into cell-type specific expression

• Functional studies:

  • Investigate CA14's role in neuronal excitability regulation

  • Explore contributions to brain pH homeostasis

  • Examine involvement in transport processes within the CNS

• Developmental neurobiology:

  • Track CA14 expression during CNS development

  • Analyze regional heterogeneity in the myelin proteome (as referenced in publications)

  • Compare expression patterns across different developmental stages

• Pathological investigations:

  • Examine changes in CA14 expression in neurological disorders

  • Correlate with alterations in brain pH regulation

  • Investigate potential therapeutic targeting of CA14

What considerations should researchers take into account when using CA14 antibodies for developmental studies?

When studying CA14 across developmental stages:

• Expression pattern variations:

  • CA14 expression changes during development of the CNS

  • Published research indicates developmental maturation affects CA14 patterns in the CNS myelin proteome

  • Consider age-appropriate positive controls

• Technical adaptations:

  • Adjust protein extraction protocols for embryonic/neonatal tissues

  • Modify fixation conditions for developmental tissues

  • Consider shorter fixation times for embryonic tissues

• Experimental design factors:

  • Include developmental time series with appropriate intervals

  • Compare multiple regions to capture spatial-temporal expression patterns

  • Account for potential isoform switching during development

• Data interpretation considerations:

  • Normalize to developmentally stable reference proteins

  • Consider relative versus absolute quantification approaches

  • Integrate with transcriptomic data when available

How can researchers effectively use CA14 antibodies to study protein interactions and complexes?

To investigate CA14's molecular interactions:

• Co-immunoprecipitation approaches:

  • Select CA14 antibodies validated for immunoprecipitation

  • Consider epitope location to avoid disrupting protein-protein interactions

  • Use mild lysis conditions to preserve native complexes

• Proximity labeling techniques:

  • Implement BioID or APEX2 proximity labeling with CA14 as the bait

  • Design constructs that maintain CA14 membrane localization

  • Account for type I membrane protein topology in experimental design

• Advanced imaging applications:

  • Apply proximity ligation assays (PLA) to visualize interactions in situ

  • Utilize FRET/FLIM with fluorescently tagged CA14 antibodies

  • Implement super-resolution microscopy to examine nanoscale distribution

• Mass spectrometry integration:

  • Combine immunoprecipitation with mass spectrometry for interaction partner identification

  • Consider crosslinking mass spectrometry for transient interactions

  • Validate key interactions with reciprocal co-immunoprecipitation